Top-News
Medtronic reports third quarter fiscal 2025 financial results
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.
Key Highlights
- Revenue of $8.3 billion increased 2.5% as reported and 4.1% organic
- GAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%
- Company reiterates full year revenue and EPS guidance
- Cardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) products
- U.S. Centers for Medicare and Medicaid (CMS) announced coverage for Renal Denervation for the treatment of Hypertension expected to become final on or before October 11, 2025
Financial Results
Medtronic reported Q3 worldwide revenue of $8.292 billion, an increase of 2.5% as reported and 4.1% on an organic basis. Organic revenue growth comparison excludes:
- Other revenue of $32 million in the current year and $53 million in the prior year; and
- Foreign currency translation of -$103 million on the remaining segments.
As reported, Q3 GAAP net income and diluted earnings per share (EPS) were $1.294 billion and $1.01, respectively, representing a decrease of 2% and an increase of 2%, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.787 billion and $1.39, respectively, representing increases of 3% and 7%, respectively.
"We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth," said Geoff Martha, Medtronic chairman and chief executive officer. "We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation, to drive growth in some of the most attractive markets in MedTech."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.037 billion increased 3.7% as reported and 5.0% organic, with mid-single digit increases in CRHF and SH&A, and a low-single digit increase in CPV, all on an organic basis.
- CRHF results included mid-single digit growth in Cardiac Rhythm Management, driven by low-double digit growth in Cardiac Pacing Therapies, including mid-20s growth in Micra™ transcatheter pacing systems; Cardiac Ablation Solutions achieved low-20s growth on rapid adoption of the PulseSelect™ and Affera™ Sphere-9™ PFA systems
- SHA results driven by high-single digit Structural Heart growth, excluding congenital, on the continued strength of the Evolut™ FX+ TAVR system, and high-single digit growth in Cardiac Surgery
- CPV growth driven by high-single digit growth in balloons and mid-single digit growth in guide catheters and drug-coated balloons
- Recent U.S. FDA approval for additional pulsed field ablation manufacturing site in Galway; immediately boosts Affera™ supply
- Expanded U.S. presence in fast-growing carotid market with exclusive Contego Medical distribution agreement; includes recently FDA approved carotid stenting system and option to acquire; Contego Medical running clinical trial on next-generation transcarotid artery revascularization (TCAR) system
- Announced CMS opened a National Coverage Analysis (NCA) on Renal Denervation for the treatment of hypertension, with coverage expected to become final on or before October 11, 2025
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.458 billion increased 4.4% as reported and 5.2% organic, with a low-double digit increase in Neuromodulation, mid-single digit increase in CST, and low-single digit increase in Specialty Therapies, all on an organic basis.
- CST driven by high-single digit Neurosurgery growth on continued adoption of the AiBLE™ ecosystem of enabling technology; CST in the U.S. grew high-single digits, winning share
- Specialty Therapies results driven by mid-single digit growth in Pelvic Health on continued adoption of the InterStim X™ system; ENT grew low-single digits on strength in PTeye™ capital and disposables; Neurovascular, excluding China, grew mid-single digit with strength in flow diversion
- Neuromodulation above market performance driven by low-double digit Pain Stim growth, including high-teens U.S. growth, on the continued launch of the Inceptiv™ spinal cord stimulator; Brain Modulation grew mid-teens globally and mid-twenties in the U.S. on the continued launch of the Percept™ RC deep brain stimulator (DBS) with BrainSense™ technology
- Received CE Mark for BrainSense™ Adaptive Deep Brain Stimulation (aDBS), a real-time closed-loop system
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.072 billion decreased 1.9% as reported and decreased 0.4% organic, with flat organic result in SE and low-single digit organic decline in ACM.
- SE results were affected by ongoing stapling segment pressures and a transient change in U.S. distributor buying patterns, partially offset by high-single digit growth in Emerging Markets and high-single digit growth in Advanced Energy on continued adoption of LigaSure™ vessel sealing technology
- ACM performance included high-single digit declines in Nellcor™ blood oxygen management products on a 30% year-over-year market decline in U.S. respiratory-related hospitalizations in the quarter; this was partially offset by high-single digit growth in Perioperative Complications
Diabetes
Revenue of $694 million increased 8.4% as reported and 10.4% organic.
- U.S. revenue grew mid-single digits on the continued adoption of the MiniMed™ 780G automated insulin delivery (AID) system, with an increase in the MiniMed™ 780G installed base and strong CGM attachment rates
- International revenue grew low-double digits on increasing CGM attachment as users upgrade to the Simplera Sync™ sensor
Guidance
Medtronic today reiterated its revenue growth and EPS guidance for FY25.
The company continues to expect FY25 organic revenue growth in the range of 4.75% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth would be in the range of 3.4% to 3.8%.
The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"EPS came in above the high end of our guidance range. We were pleased with the operational performance of the business this quarter, turning mid-single digit organic growth into leveraged earnings, highlighted by healthy gross margin improvement," said Gary Corona, Medtronic interim chief financial officer. "Looking ahead, our restored earnings power continues. We will accelerate both top and bottom line growth in Q4, resulting in high-single digit adjusted EPS growth in the back half of our fiscal year."
Video Webcast Information
Medtronic will host a video webcast today, February 18, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com.
Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025. For fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the third quarter earnings presentation, click here.
| MEDTRONIC PLC WORLD WIDE REVENUE(1) (Unaudited) | ||||||||||||||||||||||||||||
| | ||||||||||||||||||||||||||||
| | THIRD QUARTER | | | YEAR-TO-DATE | ||||||||||||||||||||||||
| | REPORTED | | | | ORGANIC | | | REPORTED | | | | ORGANIC | ||||||||||||||||
| (in millions) | FY25 | | FY24 | | Growth | | Currency | | Adjusted | | Adjusted | | Growth | | | FY25 | | FY24 | | Growth | | Currency | | Adjusted | | Adjusted | | Growth |
| Cardiovascular | $ 3,037 | | $ 2,929 | | 3.7 % | | $ (38) | | $ 3,075 | | $ 2,929 | | 5.0 % | | | $ 9,145 | | $ 8,702 | | 5.1 % | | $ (62) | | $ 9,207 | | $ 8,702 | | 5.8 % |
| Cardiac Rhythm & Heart Failure | 1,545 | | 1,470 | | 5.1 | | (18) | | 1,563 | | 1,470 | | 6.3 | | | 4,659 | | 4,408 | | 5.7 | | (26) | | 4,684 | | 4,408 | | 6.3 |
| Structural Heart & Aortic | 874 | | 843 | | 3.7 | | (13) | | 887 | | 843 | | 5.2 | | | 2,610 | | 2,475 | | 5.4 | | (21) | | 2,631 | | 2,475 | | 6.3 |
| Coronary & Peripheral Vascular | 618 | | 616 | | 0.3 | | (8) | | 626 | | 616 | | 1.6 | | | 1,876 | | 1,818 | | 3.2 | | (15) | | 1,891 | | 1,818 | | 4.0 |
| Neuroscience | 2,458 | | 2,355 | | 4.4 | | (21) | | 2,478 | | 2,355 | | 5.2 | | | 7,226 | | 6,861 | | 5.3 | | (29) | | 7,255 | | 6,861 | | 5.7 |
| Cranial & Spinal Technologies | 1,250 | | 1,204 | | 3.8 | | (9) | | 1,259 | | 1,204 | | 4.6 | | | 3,632 | | 3,465 | | 4.8 | | (15) | | 3,646 | | 3,465 | | 5.2 |
| Specialty Therapies | 732 | | 726 | | 0.8 | | (8) | | 740 | | 726 | | 1.9 | | | 2,181 | | 2,126 | | 2.6 | | (10) | | 2,191 | | 2,126 | | 3.1 |
| Neuromodulation | 476 | | 425 | | 12.0 | | (4) | | 480 | | 425 | | 12.9 | | | 1,413 | | 1,270 | | 11.2 | | (5) | | 1,417 | | 1,270 | | 11.6 |
| Medical Surgical | 2,072 | | 2,112 | | (1.9) | | (32) | | 2,104 | | 2,112 | | (0.4) | | | 6,196 | | 6,219 | | (0.4) | | (50) | | 6,246 | | 6,219 | | 0.4 |
| Surgical & Endoscopy | 1,596 | | 1,616 | | (1.2) | | (26) | | 1,622 | | 1,616 | | 0.4 | | | 4,790 | | 4,803 | | (0.3) | | (40) | | 4,829 | | 4,803 | | 0.5 |
| Acute Care & Monitoring | 476 | | 495 | | (3.9) | | (5) | | 481 | | 495 | | (2.8) | | | 1,406 | | 1,416 | | (0.7) | | (10) | | 1,417 | | 1,416 | | — |
| Diabetes | 694 | | 640 | | 8.4 | | (12) | | 706 | | 640 | | 10.4 | | | 2,027 | | 1,829 | | 10.8 | | (8) | | 2,035 | | 1,829 | | 11.3 |
| Total Reportable Segments | 8,260 | | 8,035 | | 2.8 | | (103) | | 8,363 | | 8,035 | | 4.1 | | | 24,593 | | 23,610 | | 4.2 | | (149) | | 24,742 | | 23,610 | | 4.8 |
| Other(2) | 32 | | 53 | | (41.1) | | (1) | | — | | — | | — | | | 17 | | 164 | | (89.9) | | (3) | | — | | — | | — |
| TOTAL | $ 8,292 | | $ 8,089 | | 2.5 % | | $ (104) | | $ 8,363 | | $ 8,035 | | 4.1 % | | | $ 24,610 | | $ 23,775 | | 3.5 % | | $ (152) | | $ 24,742 | | $ 23,610 | | 4.8 % |
| | |
| (1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| (3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
| (4) | The three months ended January 24, 2025 excludes $71 million of revenue adjustments related to $32 million of inorganic revenue for the transition activity noted in (2) and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $53 million of inorganic revenue related to the transition activity noted in (2). |
| (5) | The nine months ended January 24, 2025 excludes $132 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $164 million of inorganic revenue related to the transition activity noted in (2). |
| MEDTRONIC PLC U.S. REVENUE(1)(2) (Unaudited) | ||||||||||||||||||||||||
| | ||||||||||||||||||||||||
| | THIRD QUARTER | | | YEAR-TO-DATE | ||||||||||||||||||||
| | REPORTED | | ORGANIC | | | REPORTED | | ORGANIC | ||||||||||||||||
| (in millions) | FY25 | | FY24 | | Growth | | Adjusted | | Adjusted | | Growth | | | FY25 | | FY24 | | Growth | | Adjusted | | Adjusted | | Growth |
| Cardiovascular | $ 1,405 | | $ 1,373 | | 2.4 % | | $ 1,405 | | $ 1,373 | | 2.4 % | | | $ 4,242 | | $ 4,149 | | 2.2 % | | $ 4,242 | | $ 4,149 | | 2.2 % |
| Cardiac Rhythm & Heart Failure | 775 | | 745 | | 4.1 | | 775 | | 745 | | 4.1 | | | 2,309 | | 2,247 | | 2.8 | | 2,309 | | 2,247 | | 2.8 |
| Structural Heart & Aortic | 372 | | 363 | | 2.6 | | 372 | | 363 | | 2.6 | | | 1,129 | | 1,087 | | 3.9 | | 1,129 | | 1,087 | | 3.9 |
| Coronary & Peripheral Vascular | 258 | | 265 | | (2.8) | | 258 | | 265 | | (2.8) | | | 804 | | 816 | | (1.4) | | 804 | | 816 | | (1.4) |
| Neuroscience | 1,689 | | 1,556 | | 8.5 | | 1,689 | | 1,556 | | 8.5 | | | 4,931 | | 4,614 | | 6.9 | | 4,931 | | 4,614 | | 6.9 |
| Cranial & Spinal Technologies | 943 | | 875 | | 7.8 | | 943 | | 875 | | 7.8 | | | 2,724 | | 2,560 | | 6.4 | | 2,724 | | 2,560 | | 6.4 |
| Specialty Therapies | 419 | | 407 | | 3.0 | | 419 | | 407 | | 3.0 | | | 1,235 | | 1,202 | | 2.7 | | 1,235 | | 1,202 | | 2.7 |
| Neuromodulation | 327 | | 275 | | 19.0 | | 327 | | 275 | | 19.0 | | | 972 | | 852 | | 14.1 | | 972 | | 852 | | 14.1 |
| Medical Surgical | 893 | | 947 | | (5.8) | | 893 | | 947 | | (5.8) | | | 2,718 | | 2,763 | | (1.6) | | 2,718 | | 2,763 | | (1.6) |
| Surgical & Endoscopy | 623 | | 663 | | (6.1) | | 623 | | 663 | | (6.1) | | | 1,928 | | 1,971 | | (2.2) | | 1,928 | | 1,971 | | (2.2) |
| Acute Care & Monitoring | 269 | | 284 | | (5.1) | | 269 | | 284 | | (5.1) | | | 790 | | 792 | | (0.2) | | 790 | | 792 | | (0.2) |
| Diabetes | 236 | | 224 | | 5.6 | | 236 | | 224 | | 5.6 | | | 683 | | 629 | | 8.7 | | 683 | | 629 | | 8.7 |
| Total Reportable Segments | 4,223 | | 4,100 | | 3.0 | | 4,223 | | 4,100 | | 3.0 | | | 12,573 | | 12,154 | | 3.4 | | 12,573 | | 12,154 | | 3.4 |
| Other(3) | 15 | | 20 | | (26.4) | | — | | — | | — | | | 51 | | 65 | | (21.3) | | — | | — | | — |
| TOTAL | $ 4,237 | | $ 4,120 | | 2.8 % | | $ 4,223 | | $ 4,100 | | 3.0 % | | | $ 12,624 | | $ 12,219 | | 3.3 % | | $ 12,573 | | $ 12,154 | | 3.4 % |
| | |
| (1) | U.S. includes the United States and U.S. territories. |
| (2) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (3) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
| MEDTRONIC PLC INTERNATIONAL REVENUE(1) (Unaudited) | ||||||||||||||||||||||||||||
| | ||||||||||||||||||||||||||||
| | THIRD QUARTER | | | YEAR-TO-DATE | ||||||||||||||||||||||||
| | REPORTED | | | | ORGANIC | | | REPORTED | | | | ORGANIC | ||||||||||||||||
| (in millions) | FY25 | | FY24 | | Growth | | Currency | | Adjusted | | Adjusted | | Growth | | | FY25 | | FY24 | | Growth | | Currency | | Adjusted | | Adjusted | | Growth |
| Cardiovascular | $ 1,632 | | $ 1,556 | | 4.9 % | | $ (38) | | $ 1,670 | | $ 1,556 | | 7.3 % | | | $ 4,904 | | $ 4,552 | | 7.7 % | | $ (62) | | $ 4,966 | | $ 4,552 | | 9.1 % |
| Cardiac Rhythm & Heart Failure | 770 | | 726 | | 6.1 | | (18) | | 788 | | 726 | | 8.6 | | | 2,350 | | 2,161 | | 8.7 | | (26) | | 2,376 | | 2,161 | | 9.9 |
| Structural Heart & Aortic | 502 | | 480 | | 4.6 | | (13) | | 515 | | 480 | | 7.2 | | | 1,482 | | 1,389 | | 6.7 | | (21) | | 1,503 | | 1,389 | | 8.2 |
| Coronary & Peripheral Vascular | 360 | | 350 | | 2.6 | | (8) | | 368 | | 350 | | 4.9 | | | 1,072 | | 1,002 | | 7.0 | | (15) | | 1,087 | | 1,002 | | 8.5 |
| Neuroscience | 769 | | 799 | | (3.7) | | (21) | | 790 | | 799 | | (1.1) | | | 2,295 | | 2,248 | | 2.1 | | (29) | | 2,324 | | 2,248 | | 3.4 |
| Cranial & Spinal Technologies | 307 | | 329 | | (6.7) | | (9) | | 316 | | 329 | | (3.9) | | | 907 | | 905 | | 0.3 | | (15) | | 922 | | 905 | | 1.9 |
| Specialty Therapies | 313 | | 319 | | (2.0) | | (8) | | 321 | | 319 | | 0.4 | | | 947 | | 924 | | 2.4 | | (10) | | 957 | | 924 | | 3.5 |
| Neuromodulation | 149 | | 150 | | (0.7) | | (4) | | 153 | | 150 | | 1.8 | | | 441 | | 419 | | 5.4 | | (5) | | 446 | | 419 | | 6.5 |
| Medical Surgical | 1,180 | | 1,164 | | 1.3 | | (32) | | 1,211 | | 1,164 | | 4.0 | | | 3,478 | | 3,456 | | 0.6 | | (50) | | 3,528 | | 3,456 | | 2.1 |
| Surgical & Endoscopy | 973 | | 953 | | 2.1 | | (26) | | 999 | | 953 | | 4.9 | | | 2,862 | | 2,832 | | 1.1 | | (40) | | 2,902 | | 2,832 | | 2.5 |
| Acute Care & Monitoring | 206 | | 211 | | (2.3) | | (5) | | 212 | | 211 | | 0.2 | | | 616 | | 624 | | (1.4) | | (10) | | 626 | | 624 | | 0.3 |
| Diabetes | 457 | | 416 | | 9.9 | | (12) | | 470 | | 416 | | 12.9 | | | 1,344 | | 1,200 | | 12.0 | | (8) | | 1,351 | | 1,200 | | 12.6 |
| Total Reportable Segments | 4,038 | | 3,935 | | 2.6 | | (103) | | 4,141 | | 3,935 | | 5.2 | | | 12,020 | | 11,456 | | 4.9 | | (149) | | 12,169 | | 11,456 | | 6.2 |
| Other(2) | 17 | | 34 | | (49.8) | | (1) | | — | | — | | — | | | (35) | | 99 | | (134.8) | | (3) | | — | | — | | — |
| TOTAL | $ 4,055 | | $ 3,968 | | 2.2 % | | $ (104) | | $ 4,141 | | $ 3,935 | | 5.2 % | | | $ 11,986 | | $ 11,555 | | 3.7 % | | $ (152) | | $ 12,169 | | $ 11,456 | | 6.2 % |
| | |
| (1) | The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (2) | Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| (3) | The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
| (4) | The three months ended January 24, 2025 excludes $86 million of revenue adjustments related to $17 million of inorganic revenue for the transition activity noted in (2), and $103 million of unfavorable currency impact on the remaining segments. The three months ended January 26, 2024 excludes $34 million of inorganic revenue related to the transition activity noted in (2). |
| (5) | The nine months ended January 24, 2025 excludes $183 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $149 million of unfavorable currency impact on the remaining segments. The nine months ended January 26, 2024 excludes $99 million of inorganic revenue related to the transition activity noted in (2). |
| MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
| | |||||||
| | Three months ended | | Nine months ended | ||||
| (in millions, except per share data) | January 24, | | January 26, | | January 24, | | January 26, |
| Net sales | $ 8,292 | | $ 8,089 | | $ 24,610 | | $ 23,775 |
| Costs and expenses: | | | | | | | |
| Cost of products sold, excluding amortization of intangible assets | 2,779 | | 2,782 | | 8,485 | | 8,172 |
| Research and development expense | 675 | | 695 | | 2,048 | | 2,060 |
| Selling, general, and administrative expense | 2,717 | | 2,673 | | 8,129 | | 7,971 |
| Amortization of intangible assets | 416 | | 419 | | 1,243 | | 1,274 |
| Restructuring charges, net | 43 | | 20 | | 120 | | 114 |
| Certain litigation charges, net | 22 | | — | | 104 | | 105 |
| Other operating (income) expense, net | (5) | | 17 | | (38) | | (13) |
| Operating profit | 1,646 | | 1,483 | | 4,519 | | 4,091 |
| Other non-operating income, net | (72) | | (177) | | (403) | | (407) |
| Interest expense, net | 179 | | 188 | | 555 | | 517 |
| Income before income taxes | 1,540 | | 1,472 | | 4,367 | | 3,982 |
| Income tax provision | 237 | | 135 | | 737 | | 936 |
| Net income | 1,303 | | 1,337 | | 3,630 | | 3,045 |
| Net income attributable to noncontrolling interests | (9) | | (15) | | (24) | | (23) |
| Net income attributable to Medtronic | $ 1,294 | | $ 1,322 | | $ 3,606 | | $ 3,022 |
| Basic earnings per share | $ 1.01 | | $ 0.99 | | $ 2.80 | | $ 2.27 |
| Diluted earnings per share | $ 1.01 | | $ 0.99 | | $ 2.79 | | $ 2.27 |
| Basic weighted average shares outstanding | 1,282.4 | | 1,329.7 | | 1,286.7 | | 1,330.1 |
| Diluted weighted average shares outstanding | 1,286.2 | | 1,331.7 | | 1,290.6 | | 1,332.4 |
| |
| The data in the schedule above has been intentionally rounded to the nearest million. |
| MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS(1) (Unaudited) | |||||||||||||||||
| | |||||||||||||||||
| | Three months ended January 24, 2025 | ||||||||||||||||
| (in millions, except per share data) | Net | | Cost of | | Gross | | Operating | | Operating | | Income | | Net Income | | Diluted | | Effective |
| GAAP | $ 8,292 | | $ 2,779 | | 66.5 % | | $ 1,646 | | 19.9 % | | $ 1,540 | | $ 1,294 | | $ 1.01 | | 15.4 % |
| Non-GAAP Adjustments: | | | | | | | | | | | | | | | | | |
| Amortization of intangible assets | — | | — | | — | | 416 | | 5.0 | | 416 | | 339 | | 0.26 | | 18.5 |
| Restructuring and associated costs(2) | — | | (4) | | — | | 46 | | 0.6 | | 46 | | 37 | | 0.03 | | 19.6 |
| Acquisition and divestiture-related items(3) | — | | (1) | | — | | 28 | | 0.3 | | 28 | | 23 | | 0.02 | | 17.9 |
| Certain litigation charges, net | — | | — | | — | | 22 | | 0.3 | | 22 | | 18 | | 0.01 | | 22.7 |
| (Gain)/loss on minority investments(4) | — | | — | | — | | — | | — | | 68 | | 52 | | 0.04 | | 22.1 |
| Medical device regulations(5) | — | | (8) | | 0.1 | | 11 | | 0.1 | | 11 | | 9 | | 0.01 | | 18.2 |
| Certain tax adjustments, net | — | | — | | — | | — | | — | | — | | 15 | | 0.01 | | — |
| Non-GAAP | $ 8,292 | | $ 2,766 | | 66.6 % | | $ 2,169 | | 26.2 % | | $ 2,130 | | $ 1,787 | | $ 1.39 | | 15.7 % |
| Currency impact | 104 | | 61 | | (0.3) | | (4) | | (0.4) | | | | | | (0.01) | | |
| Currency Adjusted | $ 8,396 | | $ 2,827 | | 66.3 % | | $ 2,165 | | 25.8 % | | | | | | $ 1.38 | | |
| | | | | | | | | | | | | | | | | | |
| | Three months ended January 26, 2024 | ||||||||||||||||
| (in millions, except per share data) | Net | | Cost of | | Gross Für dich aus unserer Redaktion zusammengestelltDein Kommentar zum Artikel im Forum Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Weitere Artikel des AutorsThemen im Trend | ||||||||||||